Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMDA receptor alterations in major depressive disorder assessed by PET
2022-003279-41Phase 4Terminated
- Sponsor
- Medical University of Vienna
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of escitalopram in major depressive disorder (MDD) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Changes in GluN2B-containing NMDA receptor binding. Started Feb 2023; status: terminated.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2022-003279-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003279-41.